About this trial
Sarcoidosis is a systemic inflammatory disease characterized by unspecific granuloma formation. Our hypothesis is that granuloma formation and maintenance mainly relies on the overactivation of monocytes (Mo) and macrophages (Ma). To this end, the study aims (i) to define MoMa systemic signature in sarcoidosis, (ii) to characterize this signature in situ on tissue samples, and (iii) to identify causative factors that participate to the MoMa chronic overactivation. Thus, a cohort of sarcoidosis patients will be compared with tuberculosis patients. The MoMa systemic signature will be defined on whole blood (TruCulture model) and then in situ through different methods (multi-parameter spectral flow cytometry, RNA-seq, Luminex, imaging mass cytometry). The epigenome of monocytes will be studied thanks to CUT\&Tag. The MoMa systemic signature will be defined ex vivo at different time points during the course of the disease with phenotypic, transcriptomic, cytokine and functional approaches. The previously identified signature will be studied in situ and completed by the characterization of granuloma architecture and microenvironmental interactions, which could be modulated by epigenetic modifications. Hence, the epigenome of monocytes will be analyzed in two groups (sarcoidosis and tuberculosis). These results would allow to better understand sarcoidosis physiopathology and, in fine, may raise new therapeutic strategies. Finally, the study could challenge the dogma on innate immunity/auto-inflammation versus adaptive immunity/auto-immunity/memory.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male and female > 18 years old
Diagnosis of sarcoidosis and of tuberculosis
Affiliated to medical insurance
Disqualifiers
HIV infection
pregnant or breastfeeding woman
Patient under legal protection, guardianship or curators
Absence of signed consent" Secondary exclusion criteria Other causes of granulomatosis ultimately identified as sarcoidosis or tuberculosis
Trial population
Adult patients diagnosed with sarcoidosis or tuberculosis
Trial design
Cohort
Prospective
Treatments tested in this trial
blood sample
Other interventionblood sample collection
Treatment groups
Trial outcomes
Primary outcomes
macrophage activation in sarcoidosis measured by epigenomic
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
monocyte activation in sarcoidosis measured by epigenomic
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
macrophage activation in sarcoidosis measured by spatial transcriptomics
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
monocyte activation in sarcoidosis measured by spatial transcriptomics
performed on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood
Secondary outcomes
monocyte activation in tuberculosis measured by epigenomic
Identification of a pathogen that triggers sarcoidosis development by metagenomic study
identification of epigenetic modifications of monocytes by CUT&Tag method
CUT\&Tag-sequencing, also known as cleavage under targets and tagmentation, is a method used to analyze protein interactions with DNA
Identification of a diagnostic test to discriminate sarcoidosis and tuberculosis
measurement of IFNγ secretion by whole blood in response to stimulation by tuberculosis antigen
Sponsors and contacts
Click on the lead sponsor to view all of their trials.